Table 3.
Four-Year Cumulative Event Rates by Coronary Artery Disease Severity and Treatment Assignment
| Number of Events | 4- Year Event Rate | |||||
|---|---|---|---|---|---|---|
| INV | CON | INV | CON | Difference (95% CI) | Interaction P-value | |
| All-Cause Mortality | 0.89 | |||||
| One-vessel CAD ≥50% | 2 | 2 | 2.7% (0.5%, 8.8%) | 4.4% (0.7%, 13.6%) | −1.6% (−8.9%, 5.6%) | |
| One-vessel CAD ≥70% or two-vessel ≥50% | 9 | 9 | 3.7% (1.7%, 6.8%) | 3.0% (1.4%, 5.4%) | 0.7% (−2.5%, 3.9%) | |
| Two-vessel CAD ≥70% or three-vessel ≥50% or 70% proximal LAD | 18 | 17 | 5.8% (3.4%, 9.1%) | 5.0% (2.9%, 7.9%) | 0.8% (−3.0%, 4.6%) | |
| Three-vessel CAD ≥70% or two-vessel ≥70% including proximal LAD | 20 | 20 | 7.7% (4.8%, 11.5%) | 7.7% (4.7%, 11.7%) | −0.0% (−4.9%, 4.8%) | |
| MI | 0.49 | |||||
| One-vessel CAD ≥50% | 2 | 4 | 2.2% (0.4%, 7.1%) | 8.7% (2.5%, 19.9%) | −6.5% (−15.8%, 2.8%) | |
| One-vessel CAD ≥70% or two-vessel ≥50% | 25 | 21 | 8.3% (5.4%, 12.1%) | 7.3% (4.6%, 11.0%) | 1.0% (−3.7%, 5.6%) | |
| Two-vessel CAD ≥70% or three-vessel ≥50% or 70% proximal LAD | 27 | 36 | 6.8% (4.5%, 9.8%) | 9.6% (6.7%, 13.0%) | −2.8% (−6.9%, 1.3%) | |
| Three-vessel CAD ≥70% or two-vessel ≥70% including proximal LAD | 27 | 39 | 9.2% (6.1%, 12.9%) | 13.4% (9.7%, 17.7%) | −4.2% (−9.5%, 1.0%) | |
| CV Death or MI | 0.33 | |||||
| One-vessel CAD ≥50% | 3 | 4 | 3.3% (0.9%, 8.6%) | 8.7% (2.5%, 19.9%) | −5.4% (−14.9%, 4.2%) | |
| One-vessel CAD ≥70% or two-vessel ≥50% | 26 | 25 | 8.8% (5.7%, 12.8%) | 8.7% (5.6%, 12.5%) | 0.2% (−4.7%, 5.1%) | |
| Two-vessel CAD ≥70% or three-vessel ≥50% or 70% proximal LAD | 38 | 48 | 10.2% (7.2%, 13.9%) | 12.8% (9.5%, 16.7%) | −2.6% (−7.5%, 2.3%) | |
| Three-vessel CAD ≥70% or two-vessel ≥70% including proximal LAD | 34 | 50 | 11.6% (8.1%, 15.7%) | 17.9% (13.4%, 22.8%) | −6.3% (−12.4%, −0.2%) | |
| Trial Primary Endpoint | 0.49 | |||||
| One-vessel CAD ≥50% | 4 | 5 | 4.5% (1.5%, 10.4%) | 8.2% (2.7%, 17.6%) | −3.6% (−12.3%, 5.1%) | |
| One-vessel CAD ≥70% or two-vessel ≥50% | 28 | 30 | 9.4% (6.2%, 13.4%) | 10.1% (6.9%, 14.1%) | −0.7% (−5.8%, 4.4%) | |
| Two-vessel CAD ≥70% or three-vessel ≥50% or 70% proximal LAD | 43 | 51 | 11.5% (8.3%, 15.3%) | 13.2% (9.9%, 17.0%) | −1.7% (−6.6%, 3.3%) | |
| Three-vessel CAD ≥70% or two-vessel ≥70% including proximal LAD | 39 | 53 | 13.3% (9.5%, 17.6%) | 18.8% (14.3%, 23.9%) | −5.6% (−11.9%, 0.7%) | |
| CV Death | 0.42 | |||||
| One-vessel CAD ≥50% | 1 | 1 | 1.1% (0.1%, 5.4%) | 2.7% (0.2%, 12.1%) | −1.6% (−7.2%, 4.1%) | |
| One-vessel CAD ≥70% or two-vessel ≥50% | 4 | 4 | 1.6% (0.5%, 4.1%) | 1.3% (0.4%, 3.3%) | 0.3% (−1.9%, 2.5%) | |
| Two-vessel CAD ≥70% or three-vessel ≥50% or 70% proximal LAD | 14 | 14 | 4.2% (2.3%, 6.9%) | 3.7% (2.1%, 6.1%) | 0.5% (−2.6%, 3.5%) | |
| Three-vessel CAD ≥70% or two-vessel ≥70% including proximal LAD | 11 | 17 | 3.7% (1.9%, 6.4%) | 6.7% (3.9%, 10.5%) | −3.0% (−7.0%, 1.0%) | |
| Spontaneous MI | 0.51 | |||||
| One-vessel CAD ≥50% | 1 | 2 | 1.1% (0.1%, 5.4%) | 5.7% (1.0%, 16.8%) | −4.5% (−12.6%, 3.5%) | |
| One-vessel CAD ≥70% or two-vessel ≥50% | 17 | 21 | 6.0% (3.5%, 9.6%) | 7.3% (4.6%, 11.0%) | −1.3% (−5.7%, 3.1%) | |
| Two-vessel CAD ≥70% or three-vessel ≥50% or 70% proximal LAD | 15 | 27 | 4.1% (2.2%, 6.7%) | 7.0% (4.6%, 10.0%) | −2.9% (−6.4%, 0.6%) | |
| Three-vessel CAD ≥70% or two-vessel ≥70% including proximal LAD | 15 | 30 | 5.4% (3.1%, 8.6%) | 10.2% (7.0%, 14.0%) | −4.8% (−9.3%, −0.3%) | |
The trial primary endpoint was the composite of CV death, MI and hospitalization for heart failure, unstable angina or resuscitated cardiac arrest.